These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19546365)

  • 1. Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
    Iabadene H; Dallenne C; Messai Y; Geneste D; Bakour R; Arlet G
    Antimicrob Agents Chemother; 2009 Sep; 53(9):4043-4. PubMed ID: 19546365
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel genetic structure associated with an extended-spectrum beta-lactamase blaVEB gene in a Providencia stuartii clinical isolate from Algeria.
    Aubert D; Naas T; Lartigue MF; Nordmann P
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3590-2. PubMed ID: 16048993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First characterization of a Providencia stuartii clinical isolate from a Tunisian intensive care unit coproducing VEB-1-a, OXA-2, qnrA6 and aac(6')-Ib-cr determinants.
    Mahrouki S; Chihi H; Bourouis A; Ben Moussa M; Belhadj O
    Braz J Infect Dis; 2014; 18(2):211-4. PubMed ID: 24378226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
    Rodríguez C; Radice M; Perazzi B; Castro S; Juárez J; Santini P; Vay C; Famiglietti A; Gutkind G
    Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):122-6. PubMed ID: 15757582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providencia stuartii with VIM-1 metallo-beta-lactamase.
    Miriagou V; Tzouvelekis LS; Flevari K; Tsakiri M; Douzinas EE
    J Antimicrob Chemother; 2007 Jul; 60(1):183-4. PubMed ID: 17517828
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrolytic rate at low drug concentration as a limiting factor in resistance to newer cephalosporins.
    Hiraoka M; Inoue M; Mitsuhashi S
    Rev Infect Dis; 1988; 10(4):746-51. PubMed ID: 3055173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PEr 1 extended-spectrum β-lactamase among nosocomial providencia stuartii isolates in Tunisia.
    Lahlaoui H; Ben Moussa M
    Tunis Med; 2014 Apr; 92(4):258-61. PubMed ID: 25224421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First detection of TEM-116 extended-spectrum β-lactamase in a Providencia stuartii isolate from a Tunisian hospital.
    Lahlaoui H; Dahmen S; Moussa MB; Omrane B
    Indian J Med Microbiol; 2011; 29(3):258-61. PubMed ID: 21860106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.
    de Champs C; Monne C; Bonnet R; Sougakoff W; Sirot D; Chanal C; Sirot J
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1278-80. PubMed ID: 11257046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in susceptibilities of Proteeae spp. to six cephalosporins and three aminoglycosides.
    Penner JL; Preston MA; Hennessy JN; Barton LJ; Goodbody MM
    Antimicrob Agents Chemother; 1982 Aug; 22(2):218-21. PubMed ID: 6765415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PER-1 production in a urinary isolate of Providencia rettgeri.
    Bahar G; Eraç B; Mert A; Gülay Z
    J Chemother; 2004 Aug; 16(4):343-6. PubMed ID: 15332708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK; Thukral SS; Gaind R
    Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of inhibition of chromosomal beta-lactamases by third-generation cephalosporins.
    Charnas RL; Then RL
    Rev Infect Dis; 1988; 10(4):752-60. PubMed ID: 3142012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.